About ERIX
EiRx Therapeutics is a specialist provider of pre-clinical therapeutics to the pharmaceutical industry. Our unique scientific expertise and knowledge in the field of Apoptosis provide a sound base to discover and develop new medicines that will safely and selectively repair this natural process in disease. The potential benefits from these new medicines are enormous, since as many as 70% of all human disease have some defect in the control of Apoptosis.
Apoptosis - the biological process that determines whether cells in our bodies live or die...
http://www.eirx.com/index.html

Purchased some of these on the strength of the PROGRESS UPDATE looks promising.
http://moneyam.uk-wire.com/cgi-bin/articles/200603200701130254A.html

ERX interview with John Pool
http://www.wallstreetreporter.com/interview.php?id=18589&player=real
Latest News
CANCER COLLABORATION WITH BIOMERIEUX SA
http://moneyam.uk-wire.com/cgi-bin/articles/200607120700230534G.html
Biomerieux Web Site
http://www.biomerieux.com/servlet/srt/bio/portail/home
ABOUT ERX Focus Of The Month
http://www.billamag.net/focus-document-text.asp?FocusTextID=1
ERX pdf filehttp://www.eirx.com/eirx_heading_images/Yokohama2005.pdf
19/09/2006 A 50% reduction in breast tumour volume size seen with Eirx lead molecule in animal studies
http://moneyam.uk-wire.com/cgi-bin/articles/200609190700171175J.html

Past and present collaborative partners include:

* bioMieux SA
* Almac Diagnostics Ltd
* Merck & Co, Ltd
* Biofocus plc
* MGI Pharmaceuticals, Inc
* OSI Pharmaceuticals, Inc
* Sareum plc
* Regen Therapeutics plc
* SR Pharma plc

analyst note coming out shortly

results were very good, milestones confirmed as coming, but we dont know when.
short termers are the ones who will be paying the price.

zzzzzzzzzzzzz

"John K Pool"
13/11/2006 17:14
To
cc

Subject
Re: Shareholder Question





We are looking at producing an analysts note currently We are not
considering going back to the market, if at all, without some very
significant news
John
----- Original Message -----
From:
To: "John K Pool"
Sent: Monday, November 13, 2006 5:10 PM
Subject: Re: Shareholder Question


> John,
>
> Yes I understand this, but my concern is if we dont get some cash soon ERX
> will run out of cash and turn to the market, which I really am hopeing
> this
> will not be the case. I am hopeing the milestone payments will fund us for
> a number of years.
>
> As you know I commented on the marketing, we have changed broker but no
> broker update, I have noted some PI's have asked Seymore pierce why there
> is no broker note, and they say there is none, why not???, this I believe
> is putting many potential investors off.
>
> I look forward to receiving the annual report
>
> Kind regards
>

PH they have confirmed a placing for April 2007 which has to bring into question the above?

"John K Pool"
12/10/2006 09:34
To
cc

Subject
Re: Shareholder Question





Yes it is being chased as we speak
Cheers
john
----- Original Message -----
From:
To: "John K Pool"
Sent: Thursday, October 12, 2006 9:32 AM
Subject: Re: Shareholder Question


> Morning John,
>
> Many thanks for that, I did in fact go through all the news papers, and
> only found a mention in an irish paper, I did see people mention that it
> was in skye news, but I watched and did not see it, oh well.
> Can I ask, what exactly happened to the licence payment from MGI, you did
> mention this last year, I think, also I noted you also said Patent
> applications should be passed within 3-6 months but we have also passed
> that timescale.
>
>
> Many thanks

happy xmas to all

Merry Christmas and look forward to some RNS and not just you PH!

Sounds good laurie ! have a good weekend all :))

I know PH has made this a joke thread through out 2006 well many of us were here before he arrived ERX is not a joke company and should not be seen as a fast buck, ERX is a serous drug company developing some very important therapies for cancer that could one day save the life of any one of our families including ourself's, that's that bit out of the way.

They have collaborations and Intellectual Property agreement with Almac Diagnostics, bioMerieux SA, future milestones and royalties that could run into millions on the successful development of ZYC300. A similar success-based milestone arrangement pertains to the Company's licensing of drug targets to OSI Pharmaceuticals also payments could come from bioMerieux and MGI Pharma Just one small payment from any one of these companies will see the sp surge. The M/Cap is ridiculously small for such a bio company with so much going on IMO erx will have a successful placing next year, a development break through or some milestones payments in 2007 Not a share to be out of Top Up on the dips.

edjodav - 29 Dec'06 - 12:10 - 713 of 713

One of the reasons we delayed was to try and get them in, we are however chasing, but big companies don't seem to work on the same timescales as us, more glacial.
Have a good Christmas
John
----- Original Message -----
From:
To: John K Pool
Sent: Friday, December 22, 2006 12:07 PM
Subject: milestone payments


hi john i sent you an email yesterday asking when results would be out and you told me today but yet they were released yesterday after market close, you stated that you would refer to mentioning anything about milestone payments until the results had been released please would you be so kind as to let me know when you will make a statement relating to this. regards a loyal shareholder eddie davis

not long now lads

MGI PHARMA to Present at the JP Morgan 25th Annual Healthcare Conference
JPMorgan 25th Annual Healthcare Conference
MINNEAPOLIS--(BUSINESS WIRE)--MGI PHARMA, INC. (Nasdaq:MOGN) today announced that Lonnie Moulder, President and Chief Executive Officer of MGI PHARMA, will present at the JP Morgan 25th Annual Healthcare Conference in San Francisco, CA on Wednesday, January 10, 2007 at 10:30 a.m. Pacific Standard Time. Mr. Moulder will provide an overview of the Company, its products, pipeline and 2007 corporate goals.

The presentation will be webcast live and may be accessed by logging on to our corporate website at www.mgipharma.com. Please connect to the Companys website at least 15 minutes prior to the live presentation to ensure adequate time for any software download that may be necessary to listen to the webcast. An archived version of the presentation will be available through January 17, 2007.

About MGI PHARMA

MGI PHARMA, INC. is a biopharmaceutical company focused in oncology and acute care that acquires, researches, develops and commercializes proprietary products that address the unmet needs of patients. MGI PHARMA has a portfolio of proprietary pharmaceuticals, and intends to become a leading biopharmaceutical company. MGI PHARMA markets Aloxi (palonosetron hydrochloride) Injection, Dacogen (decitabine) for Injection and Gliadel Wafer (polifeprosan 20 with carmustine implant) in the United States. The Company directly markets its products in the U.S. and collaborates with partners to reach international markets.

6 days to go to blast off

Not sure but I may of heard that before !!

i agree with potatohead there is something strange!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!

Err I think its what is called more sellers than buyers,hence the drop in price,nothing strange about that.
Makes a change from PH,news not out this afternoon,but in 6 days time.PH havent you got bored of ramping this share up??I guess one day you will get it right.
Anybodys guess when news comes,just hope its sooner rather than later,otherwise i see this share continuing to fall,still i guess those lucky enough to have some spare cash will be able to top up.

EiRx Therapeutics PLC
04 January 2007

EiRx Therapeutics plc ('EiRx' or 'the Company')



Placing


The Company announces that it has placed with clients of its broker, Ellis
Stockbrokers Limited, 250,000,000 EiRx Ordinary Shares of 0.2p nominal value at
a price of 0.2p per share to raise 500,000 before expenses. The funds raised
will be used to provide additional working capital for the Company.

Application has been made for the admission of these shares to trading on AIM
with admission expected to take place on 11 January 2007.

Following the issue of these shares, the total number of Ordinary Shares with
voting rights will be 2,975,743,260.


This information is provided by RNS
The company news service from the London Stock Exchange

Well one thing for sure PH does not have a

Luckypicker - 4 Jan'07 - 17:39 - 1053 of 1069


HERE YOU GO!!!

"john"
04/01/2007 16:56
To
cc

Subject
Re: Shareholder Question


There is very good and positive reasoning behind this move and the need to take dynamic decisions is one of the reasons we are no longer responding to individuals
Regards
John
------------------
Sent with Instant Email from T-Mobile

-----Original Message-----
From:
Date: Thu, 4 Jan 2007 16:35:55
To:"John K Pool"
Subject: Fw: Shareholder Question


Dear John,

I am not very happy and I am sure many others are also not happy, re your
email below.

where is this significant news??

I think some explaining is needed here

Thanks






"John K Pool"
To

13/11/2006 17:14 cc

Subject
Re: Shareholder Question










We are looking at producing an analysts note currently We are not
considering going back to the market, if at all, without some very
significant news
John

tip off..get into GWP ...will go very high soon..sativex: drug with no harmful side effects